Bullish indicating open at $55-$60, IPO prices at $37
Cathie Wood’s ARK ETFs have released their daily trades for Tuesday, 18 March 2025, reflecting a series of strategic buy and sell decisions across a variety of sectors. Topping the list with the highest dollar-value trade, ARK notably increased its stake in Tempus AI Inc (NYSE:TEM), purchasing 171,176 shares, which amounted to an impressive $8,536,546 investment. This move underscores ARK’s growing interest in Tempus AI, a company that utilizes artificial intelligence in healthcare to personalize patient treatment.
Another significant trade included the acquisition of 113,447 shares of GitLab Inc (NASDAQ:GTLB), a web-based DevOps lifecycle tool, with a total dollar value of $5,892,437. This follows a pattern of consistent investment in GitLab, as ARK had previously bought shares on multiple occasions last week, indicating a bullish outlook on the software development company.
In the biotech sphere, ARK ETFs continued to accumulate shares of CRISPR Therapeutics AG (NASDAQ:CRSP) and Intellia Therapeutics Inc (NASDAQ:NTLA), with purchases of 67,787 and 194,844 shares, valued at $2,902,639 and $1,866,605 respectively. These transactions highlight ARK’s ongoing commitment to companies involved in gene editing technology.
Advanced Micro Devices Inc (NASDAQ:AMD), a semiconductor company, also caught ARK’s attention with the purchase of 30,324 shares, totaling $3,171,587. This investment aligns with ARK’s focus on innovative technology firms.
On the other side of the ledger, ARK executed several notable sales. The largest divestment was in UiPath Inc (NYSE:PATH), a robotic process automation vendor, with ARK selling 509,799 shares for a total of $5,495,633. This sale represents a continuation of ARK’s reduction in UiPath holdings, as evidenced by trades from the previous week.
Shares of Ansys Inc (NASDAQ:ANSS), a simulation software company, were also reduced by 5,601 shares, valued at $1,820,045, split across ARKQ and ARKX (NYSE:ARKX) ETFs. Additionally, ARK sold 2,160 shares of Meta Platforms Inc (NASDAQ:META), the parent company of Facebook, for $1,306,584.
Other sales included 103,844 shares of Illumina Inc (NASDAQ:ILMN), a genomics company, and smaller quantities of Prime Medicine Inc (NASDAQ:PRME) and Repare Therapeutics Inc (NASDAQ:RPTX), with the latter representing the smallest trade at just $7,649.
ARK’s daily trade activities offer insights into the firm’s strategic positioning and the sectors it believes will lead the next wave of innovation. Investors and market watchers alike will be keen to see how these trades align with ARK’s overall investment thesis and how they may impact the performance of the respective ETFs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.